GALT Share Price | Galectin Therapeutics, Inc. Stock Analysis & Recommendation

Q: How big is Galectin Therapeutics, Inc.?

Market Cap: As of Jun 18, Galectin Therapeutics, Inc. has a market capitalization of 151.27 million, categorized as a Micro Cap.Recent Quarterly Performance: For the latest four quarters, Galectin Therapeutics, Inc. reported net sales of 0.00 million and a net profit of -45.19 million.Balance Sheet Snapshot: As of Dec 24, the company's shareholder's funds were -103.07 million, and total assets amounted to 17.50 million.

Q: What does Galectin Therapeutics, Inc. do?

Overview:Galectin Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in drug research and development for fibrotic disease and cancer, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.Financial Snapshot:Most recent Net Profit: -10 Million (Quarterly Results - Mar 2025)Market cap: USD 151.27 Million (Micro Cap)Key Metrics:P/E: NA (Loss Making)Industry P/E: NADividend Yield: 0.00%Debt Equity: -0.90Return on Equity: 41.53%Price to Book: -1.35Contact Details:Address: 4960 Peachtree Industrial Blvd Ste 240, BERKELEY LAKE GA: 30071-1580Tel: 1 678 6203186Website: http://galectintherapeutics.com/

Q: Is Galectin Therapeutics, Inc. technically bullish or bearish?

As of 29 August 2025, the technical trend for Galectin Therapeutics, Inc. has changed from mildly bullish to bullish. The current stance is bullish with strong indicators supporting this view. The MACD is bullish on both weekly and monthly time frames, while the Bollinger Bands show a bullish signal monthly and mildly bullish weekly. Moving averages are bullish on the daily chart, and the KST is bullish on both weekly and monthly time frames. Although the Dow Theory indicates a mildly bullish stance weekly and monthly, the overall technical picture remains positive.In terms of performance, the stock has significantly outperformed the S&P 500 year-to-date with a return of 259.69% compared to the S&P 500's 12.22%. Over the past year, the stock has returned 71.22% against the S&P 500's 17.14%.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

147.64 k

Shareholding (Sep 2025)

FII

1.74%

Held by 17 FIIs

DII

93.07%

Held by 6 DIIs

Promoter

0.00%

How big is Galectin Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Galectin Therapeutics, Inc. has a market capitalization of 151.27 million and reported net sales of 0.00 million with a net profit of -45.19 million over the last four quarters. The company's shareholder's funds were -103.07 million, with total assets of 17.50 million as of Dec 24.

View full answer

What does Galectin Therapeutics, Inc. do?

22-Jun-2025

Galectin Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for fibrotic diseases and cancer, with a market cap of approximately $151.27 million. The company reported a net loss of $10 million in its most recent quarter.

View full answer

Who are in the management team of Galectin Therapeutics, Inc.?

22-Jun-2025

As of March 2022, the management team of Galectin Therapeutics, Inc. includes Richard Uihlein (Independent Chairman), Joel Lewis (CEO), Adam Allgood (Executive Director of Clinical Development), and several directors including James Czirr, Harold Shlevin, Gilbert Amelio, and Kary Eldred. They oversee the company's strategic direction and operations.

View full answer

Is Galectin Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of August 29, 2025, Galectin Therapeutics, Inc. shows a bullish trend with strong technical indicators, outperforming the S&P 500 significantly year-to-date with a return of 259.69% compared to 12.22%.

View full answer

Compare Galectin Therapeutics, Inc. with Similar Stocks

Greenwich LifeSciences, Inc.Prelude Therapeutics, Inc.XBiotech, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 205 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.90

Return on Equity

29.19%

Price to Book

-1.66

Revenue and Profits:

Net Sales:

(Quarterly Results - Sep 2025)

Net Profit:

-8 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-55.36%

6 Months

-40.73%

1 Year

74.05%

2 Years

28.5%

3 Years

40.31%

4 Years

48.65%

5 Years

19.05%

Galectin Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

-9.76%

EBIT to Interest (avg)

-20.86

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.90

Sales to Capital Employed (avg)

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

19.03%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

-1.66

EV to EBIT

-10.84

EV to EBITDA

-10.84

EV to Capital Employed

-24.69

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

Negative BV

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bearish

RSI

Bullish

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Bullish

Dow Theory

Mildly Bearish

OBV

Mildly Bullish

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 10 Schemes (5.19%)

Foreign Institutions

Held by 17 Foreign Institutions (1.74%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Sep 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Sep 2025 is 26.79% vs -7.69% in Sep 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-4.20",
          "val2": "-9.10",
          "chgp": "53.85%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "1.80",
          "val2": "1.50",
          "chgp": "20.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-2.20",
          "val2": "-0.80",
          "chgp": "-175.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-8.20",
          "val2": "-11.20",
          "chgp": "26.79%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -14.36% vs -5.93% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-42.40",
          "val2": "-38.00",
          "chgp": "-11.58%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "5.50",
          "val2": "2.80",
          "chgp": "96.43%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.60",
          "val2": "-0.40",
          "chgp": "250.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-47.00",
          "val2": "-41.10",
          "chgp": "-14.36%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY

Sep'25

Sep'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-4.20

-9.10

53.85%

Interest

1.80

1.50

20.00%

Exceptional Items

-2.20

-0.80

-175.00%

Consolidate Net Profit

-8.20

-11.20

26.79%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Sep 2024

Consolidated Net Profit

YoY Growth in quarter ended Sep 2025 is 26.79% vs -7.69% in Sep 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-42.40

-38.00

-11.58%

Interest

5.50

2.80

96.43%

Exceptional Items

0.60

-0.40

250.00%

Consolidate Net Profit

-47.00

-41.10

-14.36%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -14.36% vs -5.93% in Dec 2023

All Annual Results

Company CV

About Galectin Therapeutics, Inc.

Galectin Therapeutics, Inc.

Pharmaceuticals & Biotechnology

Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company's drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions. It uses naturally occurring, readily-available plant materials as starting material in manufacturing processes to create complex carbohydrates with specific molecular weights and other pharmaceutical properties. The Company has two product candidates, GR-MD-02 and GM-CT-01. The Company's galectin-3 inhibitor is GR-MD-02. The Company is focusing on development of GR-MD-02 intended to be used in the treatment of liver fibrosis associated with fatty liver disease (NASH), moderate to severe plaque psoriasis and in cancer therapy in combination with immune-system modifying agent(s). GM-CT-01 is a compound that continues to be explored in preclinical studies.

Company Coordinates

Company Details

4960 Peachtree Industrial Blvd Ste 240 , BERKELEY LAKE GA : 30071-1580

Tel: 1 678 6203186

http://galectintherapeutics.com/

Registrar Details